This site is intended for Healthcare professionals only.

Zydus Cadila receives EIR for Moraiya manufacturing facility


Zydus Cadila receives EIR for Moraiya manufacturing facility

Mumbai: ¬†Pharma Major, Zydus Cadila’s formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) signifying the successful closure of the audit.

The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations.

Post the audit, the plant has received several product approvals,including the final approval to market Mesalamine Delayed- Release Tablets USP, 1.2 g in the US.



Source: UNI
0 comment(s) on Zydus Cadila receives EIR for Moraiya manufacturing facility

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted